Results
gonorrhea, chlamydia
STIS, TRICHOMONIASIS, GONORRHEA
Of 2323 eligible AYA, 1743 (75%) enrolled in the trial. Among 863 eligible for STI testing, 814 (94%) provided specimens (median age of 21.8 years, 52% female, and 71% residing in rural areas). Population-weighted prevalence estimates were 5.0% (95% confidence interval [CI], 4.2%–5.8%) for gonorrhea, 17.9% (16.5%–19.3%) for chlamydia, 5.4% (4.6%–6.3%) for trichomoniasis, and 23.7% (22.2%–25.3%) for any STI. In multivariable models, female sex (adjusted odds ratio [aOR], 2.24; 95% CI, 1.48–3.09) and urban/periurban (vs. rural) residence (aOR, 1.48; 95% CI, 1.02–2.15) were associated with STIs; recent migration was associated with lower odds of STI (aOR, 0.37; 95% CI, 0.15–0.89). Among those with an STI, 53 (31.0%) were treated within 7 days; median time to treatment was 11 days (interquartile range, 6–77 days).